We have reported before on the annual preview of mAb products published by the journal mAbs at the start of each new year. For 2018, Hélène Kaplon & Janice M. Reichert, in “Antibodies to watch in 2018”, reveal a surge of antibody therapeutics granted approval in the European Union or United States in 2017. Ten antibodies were approved and are grouped as follows: five (brodalumab, dupilumab, sarilumab, guselkumab, benralizumab) are for immune-mediated disorders; four (avelumab, ocrelizumab, durvalumab, inotuzumab ozogamicin) are for cancer indications, and one (emicizumab) is for hemophilia. Continuing the momentum, nine additional antibody therapeutics are in regulatory review either in the European Union or the United States with regulatory actions expected by the end of 2018. Behind these, there are twelve antibody therapeutics in late stage clinical studies with marketing applications expected by the end of 2018 and another nineteen mAbs entering late stage studies in 2018.

Kaplon and Reichert go on to summarize available data regarding indications and studies for each of the antibody therapeutics, making this article a “must read” for keeping up with this growing field of pharmaceutical treatments.

Click to view: “Antibodies to watch in 2018”, by Hélène Kaplon & Janice M. Reichert  in mAbs, 10:2, 183-203.

Chamow & Associates assists biotechnology companies in producing novel mAb therapies for clinical testing and welcomes your inquiry.